Clinical Trial Update: An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease [Phase 3]

View source ↗

Summary

Phase 3 clinical trial of GV-971 (sodium oligomannurarate) for Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• GV-971 (Sodium oligomannate)

Snippet

Sponsor: Shanghai Greenvalley Pharmaceutical Co., Ltd. | Conditions: Mild to Moderate Alzheimer Disease, Cognitive Impairment | Phase 3 | Status: COMPLETED